推荐产品
形狀
liquid
運輸包裝
dry ice
儲存溫度
−20°C
一般說明
Biopredic′s HepaRG Induction Medium Supplement with Antibiotics can be used with all HepaRG cell lines. See user guide for detailed protocols.
法律資訊
Use of this product is subject to one or more license agreements.
HepaRG cells are patented and their use is strictly limited; consider the cells as a single use, disposable product that must be destroyed upon conclusion of a study or experiment. Propagating, reproducing, cloning, subcloning or any other use of the cells following the conclusion of a study is prohibited. Use of the cells to produce or manufacture commercial products for general sale or for use in the manufacture of products intended for general sale is prohibited. Transfer of the cells to anyone not employed within the same organization, whether for financial benefit or not, is prohibited. If you are unwilling to accept the terms of this LIMITED USE LICENSE, do not ORDER or use them and immediately return the cells for credit. Violators of this Limited Use Licesense will be prosecuted to the fullest extent of the law.
HepaRG cells are patented and their use is strictly limited; consider the cells as a single use, disposable product that must be destroyed upon conclusion of a study or experiment. Propagating, reproducing, cloning, subcloning or any other use of the cells following the conclusion of a study is prohibited. Use of the cells to produce or manufacture commercial products for general sale or for use in the manufacture of products intended for general sale is prohibited. Transfer of the cells to anyone not employed within the same organization, whether for financial benefit or not, is prohibited. If you are unwilling to accept the terms of this LIMITED USE LICENSE, do not ORDER or use them and immediately return the cells for credit. Violators of this Limited Use Licesense will be prosecuted to the fullest extent of the law.
HepaRG is a trademark of BioPredic International company
訊號詞
Danger
危險聲明
危險分類
Acute Tox. 4 Oral - Repr. 1A
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Lindsey M Ott et al.
SLAS discovery : advancing life sciences R & D, 22(5), 614-625 (2017-03-28)
Drug-induced liver injury (DILI) and drug-drug interactions (DDIs) are concerns when developing safe and efficacious compounds. We have developed an automated multiplex assay to detect hepatotoxicity (i.e., ATP depletion) and metabolism (i.e., cytochrome P450 1A [CYP1A] and cytochrome P450 3A4
Catherine C Bell et al.
Drug metabolism and disposition: the biological fate of chemicals, 45(4), 419-429 (2017-02-01)
Reliable and versatile hepatic in vitro systems for the prediction of drug pharmacokinetics and toxicity are essential constituents of preclinical safety assessment pipelines for new medicines. Here, we compared three emerging cell systems-hepatocytes derived from induced pluripotent stem cells, HepaRG
Beth Williamson et al.
Pharmacology research & perspectives, 4(5), e00264-e00264 (2016-10-08)
The nuclear pregnane X receptor (PXR) regulates the expression of genes involved in the metabolism, hepatobiliary disposition, and toxicity of drugs and endogenous compounds. PXR is a promiscuous nuclear hormone receptor (NHR) with significant ligand and DNA-binding crosstalk with the
Maxime Demazeau et al.
International journal of pharmaceutics, 524(1-2), 268-278 (2017-04-04)
In this study, we evaluated cationic liposomes prepared from diether-NH
Takafumi Tomida et al.
Journal of applied toxicology : JAT, 37(3), 382-390 (2016-08-03)
The approach for predicting the degree of drug-induced liver injury (DILI) risk was investigated quantitatively in a modified multiparametric assay using HepaRG cells. Thirty-eight drugs were classified by DILI risk into five categories based on drug labels approved by the
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门